Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M605083200 on June 20, 2006

J. Biol. Chem., Vol. 281, Issue 34, 24713-24720, August 25, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
281/34/24713    most recent
M605083200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clark, S. J.
Right arrow Articles by Day, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clark, S. J.
Right arrow Articles by Day, A. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

His-384 Allotypic Variant of Factor H Associated with Age-related Macular Degeneration Has Different Heparin Binding Properties from the Non-disease-associated Form*Formula

Simon J. Clark{ddagger}1, Victoria A. Higman{ddagger}, Barbara Mulloy§, Stephen J. Perkins, Susan M. Lea||, Robert B. Sim{ddagger}2, and Anthony J. Day{ddagger}**3

From the {ddagger}Medical Research Council (MRC) Immunochemistry Unit and ||Laboratory of Molecular Biophysics, Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, §National Institute of Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, and the Department of Biochemistry and Molecular Biology, University College London, WC1E 6BT, and the **Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, United Kingdom

Received for publication, May 26, 2006


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
A polymorphism in complement factor H has recently been associated with age-related macular degeneration (AMD), the leading cause of blindness in the elderly. A histidine rather than a tyrosine at residue position 384 in the mature protein increases the risk of AMD. Here, using a recombinant construct, we show that amino acid 384 is adjacent to a heparin-binding site in CCP7 of factor H and demonstrate that the allotypic variants differentially recognize heparin. This functional alteration may affect binding of factor H to polyanionic patterns on host surfaces, potentially influencing complement activation, immune complex clearance, and inflammation in the macula of AMD patients.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Age-related macular degeneration (AMD)4 is the leading cause of natural blindness in the Western world, and its prevalence may become greater with an increasing elderly population (1, 2). AMD manifests itself by the progressive destruction of the macula, causing central vision loss. The dry form of AMD, which accounts for 90% of cases, is associated with the presence of small yellow "drusen" deposits between the choroid and the retinal pigment epithelium that result in gradual vision loss; about 10-20% of patients with dry AMD go on to develop the more severe wet form. Recently, a common allelic variant of human complement factor H (3) has been linked to an increased risk of developing dry AMD (4-6). This variant arises from a tyrosine/histidine polymorphism at amino acid 384 in the mature protein (referred to as residue 402 in Refs. 4-6), where ~35% of individuals of European descent carry the disease-associated His-384 allele. This increases the likelihood of developing AMD by 2.7-fold and may account for 50% of the attributable risk of AMD (4). In individuals who are homozygous for the risk allele, the likelihood of AMD is increased by a factor of 7.4 (5). Recently, the His-384 allele has also been associated with an increased risk of myocardial infarction, where it has been suggested that atherosclerosis could contribute to macular degeneration (7).

Factor H is a 155-kDa plasma protein that acts as a cofactor for the breakdown of complement C3b by factor I (8). It is composed of 20 complement control protein (CCP; also termed short consensus repeats) modules (9), each of ~60 amino acids with a compact structure (10). The Y384H polymorphism is located within CCP7 (3). Factor H is believed to discriminate self from non-self by recognizing polyanionic structures on the former, such as sialic acid and the glycosaminoglycan (GAG) chains of proteoglycans (e.g. heparan sulfate (HS) and dermatan sulfate (DS)) and thus inhibits complement activation on host surfaces (11, 12). Factor H has been shown to be present in retinal blood vessels in the choroid (5) and is associated with the drusen of AMD patients (2, 13). In addition, markers of complement activation (e.g. C5b-9 and C3 fragments, including iC3b) have been detected in the Bruch's membrane and drusen of AMD patients, leading to the hypothesis that AMD results from an aberrant inflammatory process that includes inappropriate complement activation (2, 5, 13-15). Furthermore, it has been reported that the glycosaminoglycan HS is present in the macula from AMD patients but not detectable in controls (16).


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
 REFERENCES
 
Purification of Full-length Factor H from Human Serum— Factor H was purified from 400 ml of plasminogen/plasmin-depleted pooled human plasma (HD Supplies, High Wycombe, UK) (17) on a 25-ml column of Sepharose to which was coupled a mouse anti-human factor H monoclonal antibody (MRC OX23) (18).

Heparin-binding Site Predictions—Previously, coordinates for four models of intact factor H were created from x-ray and neutron scattering data for purified factor H along with homology modeling for 17 of the 20 CCPs based on known NMR structures for factor H (CCP5, CCP15, CCP16) and vaccinia coat protein CCP3 and CCP4 (19). We used three of these models (termed B, C, and D; Protein Data Bank accession code 1haq) to predict heparin-binding sites on factor H in conjunction with a heparin pentasaccharide model of heparin (20) using the program AutoDock, essentially as described before (21). All possible pairs of CCPs (e.g. CCP1-2, CCP2-3, etc.) were extracted from each model, and XPLOR version 3.8 (22) was used to add hydrogen atoms, build in the disulfide bonds, and energy-minimize the structures; three rounds of energy minimization were conducted, the first using a repulsive energy term only, the second also including a Lennard-Jones potential, and the third with added electrostatics. Autogrid version 3 was used to create the docking grid with a box size of 120 x 120 x 120 points spaced at 0.7 Å intervals, a dielectric constant of 1.0, in which the grid center was positioned at the center of the CCP pair. Autodock version 2.4 (23) was used for docking predictions using a simulated annealing protocol with 300 steps, where 128 runs were performed for each CCP pair with a heparin pentasaccharide model created previously (20). In addition, an Autodock prediction was performed for the CCP6-8 following the procedures described above.

Expression and Refolding of FHCCP6-8—Factor H cDNA corresponding to CCP6, CCP7, and CCP8 was amplified from factor H clone PE3 (9), which encodes the His-384 variant, and was modified by PCR to include NcoI and BamHI restriction sites allowing ligation into a pET14b vector (Merck, Nottingham, UK); primers, which are shown in supplemental table S1, were synthesized by Applied Biosystems (Warrington, UK). Analysis of the construct on an ABI 3730xl Prism DNA sequencer using the T7 promoter and terminator primers (see supplemental figure Fig. S1) determined that there were no changes to the expected sequence. This construct was transformed into BL21(DE3)pLysS competent cells (Merck) using the manufacturer's protocol, expressed in Escherichia coli and refolded using a method described previously for CCP modules (24). The protein was purified to homogeneity using anion exchange on a 1-ml Mono Q column (Amersham Biosciences, Buckinghamshire, UK) equilibrated in 20 mM CAPS, 130 mM NaCl, 1 mM EDTA, pH 10.0, and eluted with a gradient of 130 mM to 1 M NaCl over 20 min. The collected fractions were analyzed by SDS-PAGE, and the protein was found to be >98% pure where the protein under reducing conditions had a lower mobility than the non-reduced material. One-dimensional NMR spectroscopy at 600 MHz (pH 7.3) indicated that the protein was folded (e.g. up-field shifted methyl resonances were observed), and the presence of disulfide bonds were determined by analysis of trypsin digests by matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Protein concentrations were determined by amino acid analysis (25).

Site-directed Mutagenesis—Mutagenesis was carried out using PCR with the QuikChange site-directed mutagenesis kit (Stratagene, Amsterdam, The Netherlands), as recommended in the manufacturer's manual but using 18 amplification cycles in the reaction; primers (Applied Biosystems) are defined in table S1. Residues Lys-370, Arg-386, and Lys-387 were individually mutated to alanine in the context of the FHCCP6-8(His-384) construct and confirmed by DNA sequence analysis as above. In addition, His-384 was altered to tyrosine. The proteins were expressed, purified, and characterized by one-dimensional NMR spectroscopy and disulfide mapping as described above.

Heparin and Protein Biotinylation—For the biotinylation of unfractionated heparin (the 4th International Standard (4IS) (26, 27)), 13 µl of a 25 mg/ml solution of 1-ethyl-3-(3-dimethylaminopropyl)carbo-dimide hydrochloride (Sigma, Poole, UK) in 0.1 M MES, pH 6.5, was added to 7.91 mg of 4IS heparin in 1 ml of 0.1 M MES buffer, pH 6.5. Then 20 ml of 50 mM biotin-LC-hydrazide (Pierce, Northumberland, UK) in dimethylsulphoxide (freshly made) was added to the heparin/1-ethyl-3-(3-dimethylaminopropyl)carbo-dimide hydrochloride reaction and left to mix by rotation at room temperature overnight. The reaction mixture was dialyzed using a 500-molecular weight cut-off dialysis membrane (Pierce) against 10 liters of water. The histidine and tyrosine variants of FHCCP6-8 were biotinylated using a similar method. Briefly, 200 µg of protein in 462 µl of water was added to 124 µl 0.2 mg/ml EZlink N-hydroxysuccinimide-LC Biotin (Pierce) in 100 mM NaHCO3, pH 8.5, and rotated at room temperature for 1 h. Excess biotin was removed from the reaction mixture using a 250 x 10-mm C5 high perfomance liquid chromatography column (Phenomenex, Macclesfield, UK), equilibrated in 0.1% (v/v) trifluoroacetic acid, and the biotinylated protein was eluted with an 10-80% acetonitrile gradient over 35 min and collected manually. The protein was recovered on a centrifugal evaporator (Holbrook, NY) and reconstituted in phosphate-buffered saline (137 mM NaCl, 2.6 mM KCl, 8.2 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.3; Oxoid (Basingstoke, UK)).

Heparin Affinity Chromatography—The heparin binding properties of His-384 and Tyr-384 variants of FHCCP6-8 were compared with full-length human factor H by affinity chromatography on a HiTrap Heparin column (Amersham Biosciences) or a "home-made" column in which 20 mg of 4IS was coupled to 1.5 ml of CNBr-activated Sepharose (Sigma) in 0.1 M NaHCO3, 0.5 M NaCl, pH 8.3, using the manufacturer's protocol. The 1-ml HiTrap column and ~1-ml 4IS-column were equilibrated in 20 mM HEPES, 130 mM NaCl, 1 mM EDTA, pH 7.3. Protein (200 µg of recombinant proteins; 100 µg of full-length factor H) was loaded onto the columns (in 1 ml of equilibration buffer), and any unbound material was removed with 5 column volumes of buffer and collected in 1-ml fractions. Protein was eluted from the columns using a linear salt gradient of 130 mM to 1 M NaCl over 20 min by mixing 20 mM HEPES, 1 M NaCl, 1 mM EDTA, pH 7.3, with the equilibration buffer at a flow rate of 1 ml/min. One-ml fractions were collected and analyzed by SDS-PAGE, which demonstrated that the species eluting between 340 and 460 or between 170 and 290 mM NaCl, for the HiTrap and 4IS columns, respectively, corresponded to FHCCP6-8/factor H proteins. This approach was also used to determine the relative heparin binding activities of K370A, R386A, and K387A mutants, in which 200 µg of protein was loaded individually onto the HiTrap column.


Figure 1
View larger version (72K):
[in this window]
[in a new window]
  		FIGURE 1.
Prediction of heparin-binding site on CCP7 of factor H. In the top panel, predictions are shown for heparin pentasaccharides (green with sulfur atoms in yellow) docked onto a model of CCP7, in which CCP modules 6 and 8 (gray) were also included in the calculations; the five lowest energy complexes are illustrated. Basic amino acids potentially involved in binding are shown in cyan, and residue 384 (His variant) is in blue; scattering and analytical ultracentrifugation experiments on FHCCP6-8(His-384) indicate that these are likely to be on an accessible face of CCP7 (A. N. Fernando, S. J. Clark, H. E. Gilbert, R. B. Sim, A. J. Day, and S. J. Perkins, unpublished data). In the lower panel, the lowest energy CCP7/heparin model is shown. The binding of heparin to the His-384/Tyr-384 allotypic variants reveal that these have similar pH dependences (data not shown), indicating that a histidine residue is likely to be involved in the interaction. His-399 is a possible candidate (colored red), being the only other histidine (in addition to His-384) in CCP7.

 
Microtiter Plate Assays—The heparin/HS/DS binding activities of the FHCCP6-8(His-384) and FHCCP6-8(Tyr-384) variants (using biotinylated FHCCP6-8 constructs), and in some cases, full-length factor H (detected with an antibody) were compared using an assay in which the GAGs were immobilized on allylamine-coated EpranEx plates (28), kindly supplied by Plasso Technology Ltd., Sheffield, UK. Previously, we have shown that heparin/HS can bind non-covalently to surfaces plasma-polymerized with allylamine in such a way that these GAGs can still associate with a wide range of proteins (21, 28). The following GAG preparations were analyzed: unfractionated heparins corresponding to 2IS, 4IS, and 5IS (27); enoxaparin, dalteparin, and low molecular weight heparin from Sigma (catalog number H3400); selectively desulfated heparins prepared from 2IS heparin as described in Refs. 29 and 30; HSI and HSII preparations of HS (see Ref. 21); and DS purified from porcine mucosa and characterized by NMR as described previously (31) on a Varian Inova 500 MHz spectrometer at 60 °C in D2O. The GAGs (200 µl/well; 1 µg) were coated overnight at room temperature onto EpranEx plates in phosphate-buffered saline. Plates were blocked with 1% (w/v) bovine serum albumin (Sigma, catalog number A-4503) in standard assay buffer (20 mM HEPES, 130 mM NaCl, 0.05% (v/v) Tween 20, pH 7.3) for 90 min at 37 °C. The standard assay buffer was used for all subsequent incubations, dilutions, and washes at room temperature. The proteins were incubated at various concentrations with the immobilized glycosaminoglycans for 4 h. In the case of the biotinylated FHCCP6-8(His-384) and FHCCP6-8(Tyr-384) constructs, bound material was detected by adding 200 µl/well of a 1:10,000 dilution of ExtrAvidin alkaline phosphatase (Sigma, catalog number E-2636) for 30 min. Plates were then developed with 200 µl/well of 1 mg/ml disodium p-nitrophenylphosphate (Sigma) in 0.05 M Tris-HCl, 0.1 M NaCl, pH 9.3, and developed for 40 min, except for the DS-coated plates that were developed for 50 min. For the full-length protein, the level of binding (to 4IS, HIS, and HSII) was determined by incubation of the plates for 30 min with MRC OX23 (a monoclonal antibody against factor H (18); 1 µg/well) followed by a 1:1000 dilution of alkaline phosphatase-conjugated goat anti-mouse IgG (Sigma, catalog number A-3438) for another 30 min. The plates were then developed for 10 min as described above. The absorbance values at 405 nm were determined and corrected against blank wells (i.e. those that contained no GAGs).

Alternatively, the unlabeled FHCCP6-8(His-384), FHCCP6-8(Tyr-384), and mutant proteins (i.e. K370A, R386A, K387A in the context of the FHCCP6-8(His-384) construct) were adsorbed at 1 µg/ml in phosphate-buffered saline onto microtiter plates (Nunc Maxisorb, Kastrup, Denmark), and their ligand binding activities at pH 7.3 were determined using biotinylated 4IS heparin essentially as described in Ref. 21. Plate assays were carried out in 20 mM HEPES, 130 mM NaCl, 0.05% (v/v) Tween 20, pH 7.3, and the level of bound heparin was determined as described above for the biotinylated proteins. In these plate assays, all data points were determined in quadruplicate from each of two independent experiments.


Figure 2
View larger version (38K):
[in this window]
[in a new window]
  		FIGURE 2.
Comparison of heparin-binding properties for histidine and tyrosine variants of factor H. A and C, FHCCP6-8(His-384), FHCCP6-8(Tyr-384), and full-length factor H were analyzed by heparin affinity chromatography at pH 7.3 on either a HiTrap heparin column (A) or a home-made column in which heparin (4IS) had been coupled to CNBr-activated Sepharose (C). The proteins were eluted with a linear NaCl gradient, in which dashed and solid lines show the conductivity of eluent and absorbance, respectively. In the case of the FHCCP6-8His/Tyr constructs, all the protein adhered to the columns, whereas with full-length factor H, a small amount of a 155 kDa-species was present in the flow-through (3-5% of protein loaded), as determined by SDS-PAGE. B and D, analysis of FHCCP6-8(His-384) and FHCCP6-8(Tyr-384) proteins by microtiter plate assays (circles and squares, respectively). B, binding of biotinylated heparin (4IS) to immobilized FHCCP6-8(His-384) and FHCCP6-8(Tyr-384) proteins. D, interaction of biotinylated FHCCP6-8(His-384/Tyr-384) proteins with immobilized heparin (4IS). In B and D, values are plotted as mean absorbance (n = 8) ± S.E. All data are representative of at least two independent experiments.

 

   RESULTS AND DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
REFERENCES
 
Here we have investigated whether the Y384H polymorphism affects the interaction of factor H with the GAG heparin, as a model both for HS and for polyanions in general.

Prediction of Heparin-binding Sites on Factor H—Initially, coordinates for a theoretical model of factor H (19) and a heparin pentasaccharide model (20) were used in systematic docking calculations to predict the positions of potential heparin-binding sites using the program Autodock (21, 23). This analysis indicated that two CCP modules of factor H (7 and 20) harbor interaction sites for heparin, consistent with previous biochemical studies (32-34). In CCP7, docking calculations consistently placed the bound pentasaccharide model in close proximity to three basic amino acids (Lys-370, Arg-386, and Lys-387), the latter two of which are adjacent to residue 384 (Fig. 1).

Determination of Heparin-binding Residues in CCP7—To investigate the role of the amino acid residues in CCP7 predicted to bind heparin, a recombinant protein composed of CCP6, CCP7, and CCP8 was expressed in E. coli and then used as the basis for site-directed mutagenesis. The wild-type protein (His-384 variant, denoted FHCCP6-8(His-384)) was demonstrated to be correctly folded, having the expected disulfide bond arrangement (data not shown), and to bind to heparin in a variety of assays (Fig. 2), providing evidence that this region of factor H is involved in the recognition of polyanions. Mutants were produced in the context of this construct (see supplemental Fig. S1) so that Lys-370, Arg-386, and Lys-387 were individually altered to alanine. One-dimensional NMR spectroscopy demonstrated that the mutants all had essentially identical spectra to the wild-type protein (data not shown), indicating that these alterations do not perturb the tertiary structure of the protein. Furthermore, these proteins all had identical disulfide bond patterns. The effect of mutation on heparin binding function was assessed using affinity chromatography or using a microtiter plate assay, in which the proteins were immobilized and the binding of biotinylated heparin was determined essentially as described in Ref. 21. As can be seen from the chromatograph in Fig. 3A, the R386A and K387A mutants have substantially reduced binding activity when compared with wild-type FHCCP6-8(His-384), eluting from the heparin affinity column at lower NaCl concentrations, whereas mutation of Lys-370 to alanine had no affect. Results from the plate assay were consistent with this (Fig. 3B); however, the K370A protein showed a small reduction in binding. These data indicate that Arg-386 and Lys-387 are both likely to play an important role in heparin binding. This is consistent with an earlier study in which these amino acids were replaced with alanine in a double mutant expressed in the context of CCP1-7, which was shown to have reduced binding to heparin-bovine serum albumin (35); in this case, no structural studies were undertaken to assess the effect of mutagenesis on the protein fold. Furthermore, Giannakis et al. (35) reported that a R369A/K370A double mutant had greatly reduced heparin binding function. Our data indicate that Lys-370 has a minor contribution, if any, to the association with heparin.


Figure 3
View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 3.
Effect of mutagenesis on heparin-binding properties of His-384. Mutants K370A (squares), R386A (diamonds), and K387A (circles) were compared with wild-type protein by affinity chromatography on a HiTrap heparin column (A) and a microtiter plate assay (B) in which the binding of biotinylated heparin (4IS) to immobilized wild-type (WT) and mutant FHCCP6-8(His-384) proteins was determined. In A, the absorbance at 280 nm and the conductivity are shown, and the chromatogram is a representative example of three independent experiments. In B, all values are plotted as mean absorbance (n = 8) ± S.E.

 
Determining the Role of His-384/Tyr-384 in Heparin Binding—Given that His-384 is in close proximity to the heparin-binding residues on CCP7 (Fig. 1), it seemed plausible that this amino acid may participate in the interaction with heparin and that the histidine and tyrosine variants could have different functional activities. Therefore, FHCCP6-8(His-384) was mutated to tyrosine to generate the FHCCP6-8(Tyr-384) protein, and their heparin binding properties were compared; FHCCP6-8(Tyr-384) was shown to be folded, with correct disulfides, as before. From Fig. 2A, it is apparent that the His-384 variant elutes at lower salt strength than Tyr-384 from the HiTrap heparin affinity column (340 and 390 mM NaCl, respectively), whereas a higher salt strength is required to recover intact factor H. It is not surprising that the full-length protein binds more tightly to the affinity column given that it has at least two sites of heparin binding (i.e. CCP7 and CCP20; see Refs. 33, 34, and 36). However, the finding that it can be eluted at 460 mM NaCl, which is not substantially higher than for the FHCCP6-8(Tyr-384) protein, suggests that the heparin-interaction site in CCP7 makes a major contribution to this activity.

The relative heparin binding activities of the allotypic variants were further analyzed by microtiter plate assays. Either the proteins were immobilized and their interaction with biotinylated heparin determined (Fig. 2B), or heparin was bound to an allylamine-coated surface and used to assess the binding of the Tyr-384/His-384 proteins, in which these had been biotinylated (Fig. 2D). For these experiments, a well characterized unfractionated heparin (4IS (26, 27)), was utilized. In both cases, FHCCP6-8(Tyr-384) was shown to bind less well to the 4IS heparin than the FHCCP6-8(His-384) variant. This is the inverse of the result using affinity chromatography (Fig. 2A), which was performed on a commercial HiTrap column in which the exact source and composition of heparin has not been made known. Therefore, to rule out that this was an artifact resulting from the different assays used, we analyzed the binding of these proteins to a column to which 4IS heparin had been coupled. As can be seen from Fig. 2C, the relative binding affinities of FHCCP6-8(Tyr-384) and FHCCP6-8(His-384) are consistent with the plate assay data, in which an identical source of heparin was employed. It seems possible, therefore, that not only do the His-384/Tyr-384 allotypic variants have distinct heparin binding activities but that they can also differentiate between heparins of different structure.

Characterization of the His-384/Tyr-384-Heparin Interaction—To investigate this further, we analyzed the binding of the FHCCP6-8(Tyr-384) and FHCCP6-8(His-384) proteins to a wide range of heparin preparations. For the three unfractionated heparins tested (i.e. 2IS, 4IS, and 5IS), more of the FHCCP6-8(His-384) protein bound to the immobilized glycosaminoglycans when compared with the FHCCP6-8(Tyr-384); where the 4IS and 5IS preparations gave essentially identical results (Fig. 2D and supplemental Fig. S2A). The difference was less marked for the 2IS (Fig. 4A) due to an increased level of binding for the FHCCP6-8(Tyr-384) protein. In the case of the low molecular weight heparins, there was no difference in the binding of the two constructs to enoxaparin (Fig. S2C), and only a small difference was observed for their binding to dalteparin (Fig. S2D) and the LMr heparin obtained from Sigma (Fig. S2B). These data indicate that the results obtained for FHCCP6-8(His-384) and FHCCP6-8(Tyr-384), including their differential binding activities, are dependent on the type of heparin used and, thus, may correlate with differences in the structure/composition of these preparations. That said, it is difficult to attribute the differences in binding seen for the His-384 and Tyr-384 proteins to specific structural features. Therefore, to provide some insight into this, we investigated the effect of selective desulfation of IS2 heparin on its binding to FHCCP6-8(His-384) and FHCCP6-8(Tyr-384).

As can be seen from Fig. 4, the desulfation of heparin has a much larger effect on its interaction with the FHCCP6-8(His-384) protein when compared with FHCCP6-8(Tyr-384). In this regard, the removal of either the 2-O-sulfate (2-O-deS) or the N-sulfate (N-deS) leads to a large reduction in the binding of the His-384 variant (Fig. 4, B and E), where re-N-acetylation of the N-desulfated preparation (N-deS/re-N-Ac) has no additional/compensating effect (Fig. 4F). Interestingly, the binding of the Tyr-384 variant appears to be less sensitive to loss of these functional groups, in that its binding to the 6-O-desulfated and N-desulfated/re-N-acetylated preparations appears to be indistinguishable from the parental 2IS material. Furthermore, removal of 2-O-, 2,6-O-, or N-sulfates only has a small effect on the FHCCP6-8(Tyr-384) interaction (as determined from a comparison of the shapes of the binding curves relative to unmodified 2IS). From the above experiments, it is apparent that the FHCCP6-8(Tyr-384) protein can bind more strongly to particular heparin preparations than the FHCCP6-8(His-384) form, consistent with the data from the HiTrap affinity column (Fig. 2A). However, in other cases (i.e. 2IS, 4IS, and 5IS), it is the histidine form of the protein that exhibits greater binding activity. This analysis provides compelling evidence that the His-384/Tyr-384 allotypic variants of factor H recognize different structural features within heparin.


Figure 4
View larger version (35K):
[in this window]
[in a new window]
  		FIGURE 4.
Effect of selective desulfation on the binding of heparin to the histidine and tyrosine variants of factor H. The interaction of biotinylated FHCCP6-8(His-384) and biotinylated FHCCP6-8(Tyr-384) proteins (circles and squares, respectively) with immobilized 2IS heparin that has been untreated (A) or selectively desulfated (B-F) is shown. B, 2-O-desulfated (2-O-deS); C, 6-O-desulfated (6-O-deS); D, 2,6-O-desulfated (2,6-O-deS); E, N-desulfated (N-deS); F, N-desulfated, re-N-acetylated (N-deS/re-N-Ac). All values are plotted as mean absorbance (n = 8) ± S.E.

 
Determining Whether His-384/Tyr-384 Bind HS and DS—Unexpectedly, neither the FHCCP6-8(His-384/Tyr-384) constructs nor the full-length factor H bound to the HS preparations tested (Fig. 5); HSI and HSII have different levels of sulfation, where the latter is more highly sulfated than the former (see Ref. 21). It seems unlikely that this lack of activity is a consequence of the assay used because we have previously seen binding of another protein (TSG-6) to HSI and HSII preparations immobilized on EpranEx plates (21). However, we cannot rule out the possibility that the passive adsorption of these HS molecules to the allylamine surface masks their factor H-binding sites.

If factor H does interact with HS, as has been suggested (36), then it is likely to be through its recognition of a distinct structural feature (e.g. sulfation pattern), which is clearly present within heparin (e.g. 3-O-sulfation, which is an essential component of anti-coagulant heparan sulfate (37)) rather than being dependent on the absolute level of sulfation. In this regard, the complete desulfation of heparin abolished its binding to both the His-384 and the Tyr-384 proteins in assays in which the heparin was either immobilized or present in the solution (data not shown), indicating that at least some sulfation is required for the interaction with factor H.

The binding of the FHCCP6-8(His-384) and FHCCP6-8(Tyr-384) proteins to DS was also investigated since factor H has been previously reported to bind to this GAG (41). From Fig. 6, it can be seen that these constructs do interact with DS, albeit to a lesser degree than heparin, and appear to have somewhat different binding properties. The DS used here is of high purity, where the 1H NMR spectrum did not contain resonances attributable to heparin impurities (data not shown); signals from the H1 of N-sulfate or N-acetylated glucosamine, which do not coincide with any resonances in the DS spectrum, were absent. Furthermore, almost all the intensity in the spectrum could be assigned to signals from the repeating unit [{alpha}-L-IdoA-(1-4)-beta-D-GalNAc4Formula(1-4)], containing a few percentages of [{alpha}-L-IdoA2Formula-(1-4)-beta-D-GalNAc4Formula(1-4)]. This makes it likely, therefore, that factor H is a bona fide DS-binding protein and that the His-384/Tyr-384 allotypic forms may differentially recognize DS-containing proteoglycans in vivo. However, further analysis is clearly required to fully characterize the interaction between factor H and DS.


Figure 5
View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 5.
The heparin and HS binding activities of His-384, Tyr-384, and the full-length factor H. The binding of full-length factor H (A), FHCCP6-8(His-384) (B), and FHCCP6-8(Tyr-384) (C) to 4IS (circles), HSI (squares), or HSII (diamonds) was determined, in which these GAGs were immobilized on microtiter plates plasma-polymerized with allylamine. HSI and HSII are derived from a GAG-rich pig mucosal fraction; the HSI has a lower level of sulfation than HSII (21). Essentially identical results were obtained with HS from bovine kidney (H-9637; Sigma) (data not shown). All values are plotted as mean absorbance (n = 8) ± S.E.

 


Figure 6
View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 6.
The DS binding activities of the histidine and tyrosine variants of factor H. The interaction of biotinylated FHCCP6-8(His-384) and biotinylated FHCCP6-8(Tyr-384) proteins (circles and squares, respectively) with immobilized DS (solid symbols) when compared with LMr heparin (open symbols) is shown. In these experiments, the biotinylated proteins were investigated at 0-10 pmol/well (i.e. suboptimal for the heparin signal) to allow an accurate binding curve to be determined with DS; LMr heparin was used as a control since the His-384/Tyr-384 proteins have essentially identical binding activities to this GAG over the concentration range studied. All values are plotted as mean absorbance (n = 8) ± S.E.

 
The Consequences of Factor H-GAG Interactions for AMD— The lack of HS binding observed here notwithstanding, it is clear that the His-384 and Tyr-384 variants have differential heparin binding properties, which is likely to reflect a difference in their association with polyanionic structures on complement activator surfaces. However, age- or disease-related changes in HS structure and expression could also promote binding of one or another of the allotypic forms. Age-linked changes in GAG structure have been seen in various tissues (38-40), including DS (40), to which factor H has also been shown to bind (41), and as noted above, HS has been reported to be present only in the macula from patients with AMD (16). Furthermore, age-related changes in GAG content and sulfation, including an increase in the level of HS, occur in the trabecular meshwork, in which this is likely to be a general phenomenon in other regions of the human eye (40).

In a recent study describing the characterization of the heparin-binding site in CCP20 of human factor H (34), it has been suggested that a GAG molecule may be able to bind simultaneously to CCP7 and CCP20, stabilizing the "bent-back" structure of the protein inferred from solution studies (19). This is an attractive hypothesis given that heparin/HS often supports protein-protein interactions (i.e. in which the GAG chain is sandwiched between the two proteins). If this does indeed occur, then it is possible that the His-384/Tyr-384 allotypic variants of factor H may differ in this property depending on the nature of the GAG chain involved. Clearly, such alterations in the structural organization of factor H could have a significant effect on its functional activities (34).

Enhanced binding of factor H to developing drusen bodies (which contain cell debris and immune complexes (14, 15)) could lead to reduced complement-mediated opsonization, giving rise to impaired phagocytosis. In this regard, the cells of the retinal pigment epithelium have macrophage-like activity and are believed to have a role in the clearance of drusen (42). Macrophages also accumulate in the choroids of AMD patients (43) and may be involved in drusen uptake (44). Therefore, it seems plausible that AMD results from impaired immune complex clearance caused by enhanced binding of the disease-associated variant of factor H to polyanionic structures present in drusen, leading to reduced complement activation. The findings we report here are the first insights into the effect of the H384Y polymorphism on factor H function, providing new possibilities for therapeutic intervention in AMD.


   FOOTNOTES
 
* This work was supported by grants from the MRC. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

Formula The on-line version of this article (available at http://www.jbc.org) contains a supplemental table and two supplemental figures. Back

1 A recipient of an MRC Studentship (G78/7925). Back

2 To whom correspondence may be addressed: Dr. Robert B. Sim, MRC Immunochemistry Unit, Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK. Tel.: 44-1865-275351; Fax: 44-1865-275729; E-mail: bob.sim{at}bioch.ox.ac.uk. 3 To whom correspondence may be addressed: Faculty of Life Sciences, The University of Manchester, Oxford Rd., Manchester M13 9PT, UK. Tel.: 44-1865-275349; Fax: 44-1865-275729; E-mail: anthony.day{at}manchester.ac.uk.

4 The abbreviations used are: AMD, age-related macular degeneration; 2IS, 4IS, and 5IS, 2nd, 4th, and 5th International Standard of heparin, respectively; DS, dermatan sulfate; HS, heparan sulfate; CCP, complement control protein module; CAPS, 3-(cyclohexylamino)-1-propanesulphonic acid; MES, 4-morpholineethanesulfonic acid; GAG, glycosaminoglycan. Back


   ACKNOWLEDGMENTS
 
We thank Antony C. Willis (MRC Immunochemistry Unit, Oxford, UK) for assistance with protein characterization. We are grateful to Plasso Technology Ltd., Sheffield, UK, for provision of allylamine-coated EpranEx plates. The dermatan sulfate and international standards of heparin were provided by the NIBSC.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. Klein, R. J., Klein, B. E. K., Tomany, S. C., Meuer, S. M., and Huang, G. (2002) Ophthalmology 109, 1767-1779[CrossRef][Medline] [Order article via Infotrieve]
  2. Bok, D. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 7053-7054[Free Full Text]
  3. Day, A. J., Willis, A. C., Ripoche, J., and Sim, R. B. (1988) Immunogenetics 27, 211-214[CrossRef][Medline] [Order article via Infotrieve]
  4. Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., and Farrer, L. A. (2005) Science 308, 421-424[Abstract/Free Full Text]
  5. Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., Bracken, M. B., Ferris, F. L., Ott, J., Barnstable, C., and Hoh, J. (2005) Science 308, 385-389[Abstract/Free Full Text]
  6. Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., Schnetz-Boutaud, N., Agarwal, A., Postel, E. A., and Pericak-Vance, M. A. (2005) Science 308, 419-421[Abstract/Free Full Text]
  7. Kardys, I., Klaver, C. W., Despriet, D. G., Bergen, A. A. B., Uitterlinden, A. G., Hofman, A., Oostra, B. A., Van Duijn, C. M., de Jong, P. T. V. M., and Witteman, J. C. M. (2006) J. Am. Coll. Cardiol. 47, 1568-1575[Abstract/Free Full Text]
  8. Pangburn, M. K. (2000) Immunopharmacology 49, 149-157[CrossRef][Medline] [Order article via Infotrieve]
  9. Ripoche, J., Day, A. J., Harris, T. J. R., and Sim, R. B. (1988) Biochem. J. 249, 593-602[Medline] [Order article via Infotrieve]
  10. Norman, D. G., Barlow, P. N., Baron, M., Day, A. J., Sim, R. B., and Campbell, I. D.1991 J. Mol. Biol. 219, 717-725[CrossRef][Medline] [Order article via Infotrieve]
  11. Kazatchkine, M. D., Fearon, D. T., and Austen, K. F. (1979) J. Immunol. 122, 75-81[Abstract/Free Full Text]
  12. Carreno, M. P., Labarre, D., Maillet, F., Jozefowicz, M., and Kazatchkine, M. D. (1989) Eur. J. Immunol. 19, 2145-2150[Medline] [Order article via Infotrieve]
  13. Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., Smith, R. J. H., Silvestri, G., Russell, S. R., Klaver, C. C. W., Barbazetto, I., Chang, S., Yannuzzi, L. A., Barile, G. R., Merriam, J. C., Smith, R. T., Olsh, A. K., Bergeron, J., Zernant, J., Merriam, J. E., Gold, B., Dean, M., and Allikments, R. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 7227-7232[Abstract/Free Full Text]
  14. Mullins, R. F., Russell, S. R., Anderson, D. H., and Hageman, G. S. (2000) FASEB J. 14, 835-846[Abstract/Free Full Text]
  15. Johnson, L. V., Ozaki, S., Staples, M. K., Erickson, P. A., and Anderson, D. H. (2000) Exp. Eye Res. 70, 441-449[CrossRef][Medline] [Order article via Infotrieve]
  16. Kliffen, M., Mooy, C. M., Luider, T. M., Huijmans, J. G. M., Kerkvliet, S., and de Jong, P. T. V. M. (1996) Arch. Ophthalmol. 114, 1009-1014[Abstract/Free Full Text]
  17. Sim, R. B., Day, A. J., Moffatt, B. E., and Fontaine, M. (1993) Methods Enzymol. 223, 13-35[Medline] [Order article via Infotrieve]
  18. Sim, E., Palmer, M. S., Puklavec, M., and Sim, R. B. (1983) Biosci. Rep. 3, 1119-1131[CrossRef][Medline] [Order article via Infotrieve]
  19. Aslam, M., and Perkins, S. J. (2001) J. Mol. Biol. 309, 1117-1138[CrossRef][Medline] [Order article via Infotrieve]
  20. Mulloy, B., and Forster, M. J. (2000) Glycobiology 10, 1147-1156[Abstract/Free Full Text]
  21. Mahoney, D. J., Mulloy, B., Forster, M. J., Blundell, C. D., Fries, E., Milner, C. M., and Day, A. J. (2005) J. Biol. Chem. 280, 27044-27055[Abstract/Free Full Text]
  22. Brünger, A. T. (1992) XPLOR: A System for X-ray Crystallography and NMR, Version 3.1. Yale University Press, New Haven, CT
  23. Morris, G. M., Goodshell, D. S., Huey, R., and Olsen, A. J. (1996) J. Comput.-Aided Mol. Des. 10, 293-304
  24. White, J., Lukacik, P., Esser, D., Steward, M., Giddings, N., Bright, J. R., Fritchley, S. J., Morgan, B. P., Lea, S. M., Smith, G. P., and Smith, R. A. G. (2004) Protein Sci. 9, 2406-2415
  25. Day, A. J., Aplin, R. T., and Willis, A. C. (1996) Protein Expression Purif. 8, 1-16[Medline] [Order article via Infotrieve]
  26. Thomas, D. P., Curtis, A. D., and Barrowcliffe, T. W. (1984) Thromb. Haemostasis 52, 148-153[Medline] [Order article via Infotrieve]
  27. Mulloy, B., Gray, E., and Barrowcliffe, T. W. (2000) Thromb. Haemostasis 84, 1052-1056[Medline] [Order article via Infotrieve]
  28. Mahoney, D. J., Whittle, J. D., Milner, C. M., Clark, S. J., Mulloy, B., Buttle, D. J., Jones, G. C., Day, A. J., and Short, R. D. (2004) Anal. Biochem. 330, 123-129[CrossRef][Medline] [Order article via Infotrieve]
  29. Mulloy, B., Forster, M. J., Jones, C., Drake, A. F., Johnson, E. A., and Davies, D. B. (1994) Carbohydr. Res. 255, 1-26[CrossRef][Medline] [Order article via Infotrieve]
  30. Ostrovsky, O., Gallagher, J. T., Mulloy, B., Fernig, D. G., Berman, B., and Ron, D. (2002) J. Biol. Chem. 277, 2444-2453[Abstract/Free Full Text]
  31. Pavão, M. S. G., Mourão, P. A. S., Mulloy, B., and Tollefsen, D. M. (1995) J. Biol. Chem. 270, 31027-31036[Abstract/Free Full Text]
  32. Blackmore, T. K., Sadlon, T. A., Ward, H. W., Lublin, D. M., and Gordon, D. L. (1996) J. Immunol. 157, 5422-5427[Abstract]
  33. Blackmore, T. K., Hellwage, J., Sadlon, T. A., Higgs, N. Zipfel, P. F., Ward, H. M., and Gordon, D. L. (1998) J. Immunol. 160, 3342-3348[Abstract/Free Full Text]
  34. Herbert, A. P., Uhrin, D., Lyon, M., Pangburn, M. K., and Barlow, P. N. (2006) J. Biol. Chem. 281, 16512-16520[Abstract/Free Full Text]
  35. Giannakis, E., Jokiranta, T. S., Male, D. A., Ranganathan, S., Ormsby, R. J., Fischetti, V. A., Mold, C., and Gordon, D. L. (2003) Eur. J. Immunol. 33, 962-969[CrossRef][Medline] [Order article via Infotrieve]
  36. Pangburn, M. K., Atkinson, M. A. L., and Meri, S. (1991) J. Biol. Chem. 266, 16847-16853[Abstract/Free Full Text]
  37. Girardin, E. P., HajMohammadi, S., Birmele, B., Helisch, A., Shworak, N. W., and de Agostini, A. I. (2005) J. Biol. Chem. 280, 38059-38070[Abstract/Free Full Text]
  38. Lauder, R. M., Huckerby, T. N., Nieduszynski, I. A., and Plaas, A. H. K. (1998) Biochem. J. 330, 753-757[Medline] [Order article via Infotrieve]
  39. Carrino, D. A., Onnerfjord, P., Sandy, J. D., Cs-Szabo, G., Scott, P. G., Sorrell, J. M., Heinegard, D., and Caplan, A. I. (2003) J. Biol. Chem. 278, 17566-17572[Abstract/Free Full Text]
  40. Cavallotti, C., Feher, J., Pescosolido, N., and Sagnelli, P. (2004) Ophthalmic Res. 36, 211-217[CrossRef][Medline] [Order article via Infotrieve]
  41. Saito, A., and Munakata, H. (2005) J. Biochem. 137, 225-233[Abstract/Free Full Text]
  42. Ambati, J., Anand, A., Fernandez, S., Sakurai, E., Lynn, B. C., Kuziel, W. A., Rollins, B. J., and Ambati, B. K. (2003) Nat. Med. 9, 1390-1397[CrossRef][Medline] [Order article via Infotrieve]
  43. Penfold, P. L., Madigan, M. C., Gillies, M. C., and Provis, J. M. (2001) Prog. Retin. Eye Res. 20, 385-414[CrossRef][Medline] [Order article via Infotrieve]
  44. Killingsworth, M. C., Sarks, J. P., and Sarks, S. H. (1990) Eye (Lond.) 4, 613-621

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 IOVSHome page
B. Rohrer, Q. Long, B. Coughlin, R. B. Wilson, Y. Huang, F. Qiao, P. H. Tang, K. Kunchithapautham, G. S. Gilkeson, and S. Tomlinson
A Targeted Inhibitor of the Alternative Complement Pathway Reduces Angiogenesis in a Mouse Model of Age-Related Macular Degeneration
Invest. Ophthalmol. Vis. Sci., July 1, 2009; 50(7): 3056 - 3064.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Orth, A. B. Khan, A. Naim, K. Grif, J. Brockmeyer, H. Karch, M. Joannidis, S. J. Clark, A. J. Day, S. Fidanzi, et al.
Shiga Toxin Activates Complement and Binds Factor H: Evidence for an Active Role of Complement in Hemolytic Uremic Syndrome
J. Immunol., May 15, 2009; 182(10): 6394 - 6400.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
K. C.M.C. Koeijvoets, S. P. Mooijaart, G. M. Dallinga-Thie, J. C. Defesche, E. W. Steyerberg, R. G.J. Westendorp, J. J.P. Kastelein, P. M. van Hagen, and E. J.G. Sijbrands
Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia
Eur. Heart J., March 1, 2009; 30(5): 618 - 623.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Hakobyan, C. L. Harris, C. W. van den Berg, M. C. Fernandez-Alonso, E. G. de Jorge, S. R. de Cordoba, G. Rivas, P. Mangione, M. B. Pepys, and B. P. Morgan
Complement Factor H Binds to Denatured Rather than to Native Pentameric C-reactive Protein
J. Biol. Chem., November 7, 2008; 283(45): 30451 - 30460.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Q. Schmidt, A. P. Herbert, D. Kavanagh, C. Gandy, C. J. Fenton, B. S. Blaum, M. Lyon, D. Uhrin, and P. N. Barlow
A New Map of Glycosaminoglycan and C3b Binding Sites on Factor H
J. Immunol., August 15, 2008; 181(4): 2610 - 2619.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
R. J. Ormsby, S. Ranganathan, J. C. Tong, K. M. Griggs, D. P. Dimasi, A. W. Hewitt, K. P. Burdon, J. E. Craig, J. Hoh, and D. L. Gordon
Functional and Structural Implications of the Complement Factor H Y402H Polymorphism Associated with Age-Related Macular Degeneration
Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 1763 - 1770.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. J. Coffey, C. Gias, C. J. McDermott, P. Lundh, M. C. Pickering, C. Sethi, A. Bird, F. W. Fitzke, A. Maass, L. L. Chen, et al.
Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction
PNAS, October 16, 2007; 104(42): 16651 - 16656.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
B. E. Prosser, S. Johnson, P. Roversi, A. P. Herbert, B. S. Blaum, J. Tyrrell, T. A. Jowitt, S. J. Clark, E. Tarelli, D. Uhrin, et al.
Structural basis for complement factor H linked age-related macular degeneration
J. Exp. Med., October 1, 2007; 204(10): 2277 - 2283.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. P. Herbert, J. A. Deakin, C. Q. Schmidt, B. S. Blaum, C. Egan, V. P. Ferreira, M. K. Pangburn, M. Lyon, D. Uhrin, and P. N. Barlow
Structure Shows That a Glycosaminoglycan and Protein Recognition Site in Factor H Is Perturbed by Age-related Macular Degeneration-linked Single Nucleotide Polymorphism
J. Biol. Chem., June 29, 2007; 282(26): 18960 - 18968.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. P. Sjoberg, L. A. Trouw, S. J. Clark, J. Sjolander, D. Heinegard, R. B. Sim, A. J. Day, and A. M. Blom
The Factor H Variant Associated with Age-related Macular Degeneration (His-384) and the Non-disease-associated Form Bind Differentially to C-reactive Protein, Fibromodulin, DNA, and Necrotic Cells
J. Biol. Chem., April 13, 2007; 282(15): 10894 - 10900.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. T. Johnson, K. E. Betts, M. J. Radeke, G. S. Hageman, D. H. Anderson, and L. V. Johnson
Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid
PNAS, November 14, 2006; 103(46): 17456 - 17461.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
281/34/24713    most recent
M605083200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clark, S. J.
Right arrow Articles by Day, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clark, S. J.
Right arrow Articles by Day, A. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement